載入...
Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer
Pancreatic cancer remains a clinical challenge, thus new therapies are urgently needed. The selective Wee1 inhibitor MK-1775 has demonstrated promising results when combined with DNA damaging agents, and more recently with CHK1 inhibitors in various malignancies. We have previously demonstrated that...
Na minha lista:
| 發表在: | Cancer Lett |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4282784/ https://ncbi.nlm.nih.gov/pubmed/25458954 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2014.10.015 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|